Compass Therapeutics (CMPX) EBITDA Margin (2024)

Compass Therapeutics' (CMPX) quarterly EBITDA Margin came in at 1538.47% in Q2 2024.

Compass Therapeutics (CMPX) EBITDA Margin (2024) Analysis & Trends

Compass Therapeutics has disclosed EBITDA Margin across 1 years of filings, most recently posting 1538.47% for Q2 2024.

EBITDA Margin for Q2 2024 came in at 1538.47%, changed N/A year-over-year; the trailing twelve-month figure through Jun 2025 was 7262.24% (down 175329.0% YoY), and the FY2024 annual result was 5788.47%, changed N/A from the prior year.
EBITDA Margin came in at 1538.47% for Q2 2024 at Compass Therapeutics.
In the past five years, EBITDA Margin ranged from a high of 1538.47% in Q2 2024 to a low of 1538.47% in Q2 2024.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-6.43%
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	38.10%
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Compass Therapeutics	387.71 Mn	193.02 Mn	-	-

Historic Data

Download Data

Date	Value
Jun 30, 2024	-1,538.47%